Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Circassia Group Plc
  6. Summary
    CIR   GB00BJVD3B28

CIRCASSIA GROUP PLC

(CIR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/08/2021 06/09/2021 06/10/2021 06/11/2021 06/14/2021 Date
34.6(c) 33.7(c) 33(c) 34(c) 33.1(c) Last
147 041 180 921 92 429 775 859 174 717 Volume
-0.43% -2.60% -2.08% +3.03% -2.65% Change
More quotes
Financials
Sales 2021 26,6 M 37,5 M 37,5 M
Net income 2021 - - -
Net Debt 2021 5,21 M 7,35 M 7,35 M
P/E ratio 2021 -
Yield 2021 -
Sales 2022 80,9 M 114 M 114 M
Net income 2022 - - -
Net Debt 2022 5,28 M 7,45 M 7,45 M
P/E ratio 2022 -
Yield 2022 -
Capitalization 138 M 195 M 195 M
EV / Sales 2021 5,40x
EV / Sales 2022 1,77x
Nbr of Employees 162
Free-Float 44,3%
More Financials
Company
Circassia Group Plc, formerly Circassia Pharmaceuticals Plc, is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company is primarily focused on offering its commercialized asthma management products directly to specialist physicians in various markets. The Company’s NIOX products are used to improve asthma and offers a portfolio of asthma and chronic obstructive pulmonary... 
Sector
Pharmaceuticals
Calendar
09/30Earnings Release
More about the company
Ratings of Circassia Group Plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CIRCASSIA GROUP PLC
05/26BEYOND AIR  : Reaches Settlement Deal with Circassia on LungFit; Shares Rise Pre..
MT
03/24CIRCASSIA  : Preliminary results for the year ended 31 december 2020
PU
03/24CIRCASSIA  : Earnings Flash (CIR.L) CIRCASSIA GROUP Reports FY20 Revenue GBP23.9..
MT
03/24CIRCASSIA  : Earnings Flash (CIR.L) CIRCASSIA GROUP Reports FY20 Loss GBP-0.07
MT
2020CIRCASSIA  : Interim results for the six months ended 30 june 2020
PU
2020CIRCASSIA PHARMACEUTICALS  : Grant of options
PU
2020CIRCASSIA PHARMACEUTICALS  : Issue of Equity
PU
2020CIRCASSIA PHARMACEUTICALS  : Further re Board appointment
PU
2020CIRCASSIA PHARMACEUTICALS  : Announces Business Update
PU
2019CIRCASSIA PHARMACEUTICALS  : Grant of Options
PU
2019CIRCASSIA PHARMACEUTICALS  : Update on Circassia's Licensing Agreement with Beyo..
PU
2019CIRCASSIA PHARMACEUTICALS  : Update on Licensing Agreement with BeyondAir Inc.
PU
2019CIRCASSIA PHARMACEUTICALS  : Announces Board Changes
PU
2019CIRCASSIA PHARMACEUTICALS  : Announces Duaklir® US Launch at American College of..
PU
2019CIRCASSIA PHARMACEUTICALS  : US launch of Duaklir at CHEST 2019
PU
More news
News in other languages on CIRCASSIA GROUP PLC
04/15LA MINUTE DURABLE  : Déforestation, marché ESG et Fukushima
More news
Analyst Recommendations on CIRCASSIA GROUP PLC
More recommendations
Chart CIRCASSIA GROUP PLC
Duration : Period :
Circassia Group Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIRCASSIA GROUP PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price
Last Close Price 0,33 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
Steven Harris Chief Executive Officer
Michael Roy David Roller CFO & Executive Director
Ian Roy Johnson Executive Chairman
Roderick Peter Hafner Senior Vice President-Research & Development
Jonathan Emms Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CIRCASSIA GROUP PLC17.38%200
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857